This invention relates to mutated CMVpp65, a viral structural protein which
activates cell mediated immunity in humans infected with CMV. The
mutations remove undesirable protein kinase activity naturally present in
the protein and make it suitable for the production of both DNA and
protein vaccines. Therefore, the invention provides proteins and DNAs, as
well as vaccines comprising the proteins and DNAs, including cellular
vaccines and vectors. Other embodiments of the invention relate to methods
of enhancing immune response and vaccinating against CMV, including gene
therapy methods and vectors.
